BR9811744A - Conjugados contendo o homeodomìnio de antenapédia - Google Patents
Conjugados contendo o homeodomìnio de antenapédiaInfo
- Publication number
- BR9811744A BR9811744A BR9811744-0A BR9811744A BR9811744A BR 9811744 A BR9811744 A BR 9811744A BR 9811744 A BR9811744 A BR 9811744A BR 9811744 A BR9811744 A BR 9811744A
- Authority
- BR
- Brazil
- Prior art keywords
- antenapedia
- homeodomain
- conjugates containing
- region
- conjugates
- Prior art date
Links
- 102000009331 Homeodomain Proteins Human genes 0.000 title abstract 2
- 108010048671 Homeodomain Proteins Proteins 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Insects & Arthropods (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Variable-Direction Aerials And Aerial Arrays (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9718609.2A GB9718609D0 (en) | 1997-09-02 | 1997-09-02 | Fusion protein |
| PCT/GB1998/002628 WO1999011809A1 (en) | 1997-09-02 | 1998-09-02 | Conjugates that contain the homeodomain of antennapedia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9811744A true BR9811744A (pt) | 2002-01-02 |
Family
ID=10818419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9811744-0A BR9811744A (pt) | 1997-09-02 | 1998-09-02 | Conjugados contendo o homeodomìnio de antenapédia |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7968512B2 (enExample) |
| EP (1) | EP1009847A1 (enExample) |
| JP (1) | JP2001514858A (enExample) |
| AU (1) | AU737829B2 (enExample) |
| BR (1) | BR9811744A (enExample) |
| CA (1) | CA2301157A1 (enExample) |
| GB (1) | GB9718609D0 (enExample) |
| IL (2) | IL134602A0 (enExample) |
| NZ (1) | NZ503007A (enExample) |
| WO (1) | WO1999011809A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2273192A1 (en) * | 1996-12-02 | 1998-06-11 | Wake Forest University | Inactivation of hiv co-receptors as therapy for hiv infection |
| CA2314267A1 (en) * | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| CA2350882C (en) | 1998-11-12 | 2011-02-22 | Life Technologies Corporation | Transfection reagents |
| ES2318906T3 (es) | 1998-11-13 | 2009-05-01 | Cyclacel Limited | Vectores de transposicion derivados de helice 3 de homeodominio de antennapedia. |
| EP1140202A1 (en) | 1998-12-24 | 2001-10-10 | Ucb S.A. | Peptidic product, process and composition |
| US6773920B1 (en) | 1999-03-31 | 2004-08-10 | Invitrogen Corporation | Delivery of functional protein sequences by translocating polypeptides |
| AU775001B2 (en) * | 1999-03-31 | 2004-07-15 | Invitrogen Corporation | Delivery of functional protein sequences by translocating polypeptides |
| US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| AU3368301A (en) * | 2000-01-07 | 2001-07-16 | Artemis Pharmaceuticals Gmbh | Transduction of recombinases for inducible gene targeting |
| EP1118668A1 (en) * | 2000-01-07 | 2001-07-25 | ARTEMIS Pharmaceuticals GmbH | Transduction of recombinases for inducible gene targeting |
| GB0003284D0 (en) * | 2000-02-15 | 2000-04-05 | Secr Defence Brit | Anti-viral therapy |
| IL151910A0 (en) * | 2000-04-12 | 2003-04-10 | Implyx Ltd | Compositions for drug delivery |
| DE10027777A1 (de) * | 2000-06-07 | 2001-12-13 | Otogene Ag | Transfektionsverfahren |
| GB0015090D0 (en) * | 2000-06-20 | 2000-08-09 | Implyx Ltd | Gene-activating conjugates |
| KR100374050B1 (ko) * | 2000-07-26 | 2003-03-03 | 최수영 | 세포침투성 융합단백질, 이를 코딩하는 재조합폴리뉴클레오타이드 및 발현벡터 |
| WO2002020737A2 (en) * | 2000-09-07 | 2002-03-14 | Vanderbilt University | Genome engineering by cell-permeable dna site-specific recombinases |
| US6472176B2 (en) * | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
| US7442686B2 (en) | 2001-04-12 | 2008-10-28 | Bioaxone Therapeutique Inc. | Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions |
| CA2367636C (en) | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
| WO2002098365A2 (en) * | 2001-06-07 | 2002-12-12 | Skinmedica, Inc. | Conditioned cell culture media and uses thereof |
| US20050136040A1 (en) * | 2001-10-11 | 2005-06-23 | Imperial College Innovations Limited | Control of gene expression using a complex of an oligonucleotide and a regulatory peptide |
| GB0124391D0 (en) * | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| DE102007041655A1 (de) | 2007-09-03 | 2009-03-05 | Medicyte Gmbh | Vermehrung von primären Zellen und deren Verwendung |
| US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
| AU2010238346A1 (en) | 2009-04-14 | 2011-11-03 | Trojan Technologies Ltd. | Therapeutic Antennapedia-antibody molecules and methods of use thereof |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| DE102010041958A1 (de) | 2010-10-04 | 2012-04-05 | Medicyte Gmbh | Geeignete Hepatozyten für in-vitro Genotoxitätstests |
| WO2012154684A2 (en) * | 2011-05-06 | 2012-11-15 | University Of Rochester | Method of preventing development of psoriatic lesions |
| WO2012174028A2 (en) * | 2011-06-13 | 2012-12-20 | The Board Of Trustees Of The University Of Illinois | Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion |
| CA3233345A1 (en) | 2012-04-09 | 2013-10-17 | Case Western Reserve University | Compositions and methods for inhibiting the activity of lar family phosphatases |
| WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| AU2014310360B2 (en) * | 2013-06-11 | 2019-10-24 | PPL (BVI) Limited | Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides |
| EP2927685A1 (en) | 2014-04-02 | 2015-10-07 | Medicyte GmbH | Suitable hepatocytes for in-vitro hepatitis tests |
| US10195280B2 (en) | 2014-07-15 | 2019-02-05 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| RU2708375C2 (ru) | 2015-03-02 | 2019-12-06 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс | Пептиды для ингибирования ангиогенеза |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| CA3020344A1 (en) | 2016-04-07 | 2017-10-12 | Case Western Reserve University | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| EP3612191B1 (en) | 2017-04-19 | 2026-03-11 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| AU2018301399B2 (en) | 2017-07-11 | 2024-08-29 | Case Western Reserve University | Compositions and methods for treating myelin disorders |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2739621B1 (fr) * | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
-
1997
- 1997-09-02 GB GBGB9718609.2A patent/GB9718609D0/en active Pending
-
1998
- 1998-09-02 IL IL13460298A patent/IL134602A0/xx active IP Right Grant
- 1998-09-02 BR BR9811744-0A patent/BR9811744A/pt not_active Application Discontinuation
- 1998-09-02 JP JP2000508817A patent/JP2001514858A/ja active Pending
- 1998-09-02 AU AU88776/98A patent/AU737829B2/en not_active Ceased
- 1998-09-02 EP EP98940453A patent/EP1009847A1/en not_active Withdrawn
- 1998-09-02 WO PCT/GB1998/002628 patent/WO1999011809A1/en not_active Ceased
- 1998-09-02 NZ NZ503007A patent/NZ503007A/xx not_active IP Right Cessation
- 1998-09-02 CA CA002301157A patent/CA2301157A1/en not_active Abandoned
-
2000
- 2000-02-17 IL IL134602A patent/IL134602A/en not_active IP Right Cessation
-
2004
- 2004-02-27 US US10/789,403 patent/US7968512B2/en not_active Expired - Lifetime
-
2011
- 2011-06-24 US US13/168,167 patent/US8735340B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ503007A (en) | 2000-11-24 |
| IL134602A0 (en) | 2001-04-30 |
| JP2001514858A (ja) | 2001-09-18 |
| US20080317773A1 (en) | 2008-12-25 |
| US7968512B2 (en) | 2011-06-28 |
| US8735340B2 (en) | 2014-05-27 |
| AU737829B2 (en) | 2001-08-30 |
| GB9718609D0 (en) | 1997-11-05 |
| IL134602A (en) | 2006-10-31 |
| CA2301157A1 (en) | 1999-03-11 |
| US20110256168A1 (en) | 2011-10-20 |
| WO1999011809A1 (en) | 1999-03-11 |
| AU8877698A (en) | 1999-03-22 |
| EP1009847A1 (en) | 2000-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ503007A (en) | Conjugates that contain the homeodomain of antennapedia | |
| BR9915548A (pt) | Proteìnas de fusão de interferon-beta e usos | |
| CY1108007T1 (el) | Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης | |
| BR9504791B1 (pt) | composto de polipeptìdeo e composição farmacêutica. | |
| AR019818A1 (es) | Un inmunoconjugado de miostatina. | |
| EP0611573A3 (en) | Bioactive cellulose amino compounds conjugates. | |
| ES2077666T3 (es) | Proteina de union a fibronectina y su preparacion. | |
| EE9800306A (et) | Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad | |
| BRPI9810519B1 (pt) | derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. | |
| BR9808348A (pt) | Alimento medicinal para diabéticos | |
| LU91342I9 (enExample) | ||
| BR9709395A (pt) | Calçado aperfeiçoado | |
| BR9608449A (pt) | Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. | |
| NZ263344A (en) | Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use | |
| BR9807655A (pt) | Uso de inibidores de lipase gastrintestinal. | |
| BR9808875A (pt) | Combinação de analgésicos | |
| BR9911917A (pt) | Composições compreendendo análogos de gaba e cafeìna | |
| AU634280B2 (en) | Anticoagulant peptides | |
| ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
| PT1012186E (pt) | Utilizacao de produto(s) da proteina kgf e de produto(s) da proteina glp-2 para a preparacao de um medicamento | |
| BR9714376A (pt) | Antagonistas de somatostatina | |
| BR9910454A (pt) | Preparações efervescentes | |
| PT929299E (pt) | 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos | |
| TR200000416T2 (tr) | Neisseria loctoferrin bağlayıcı protein. | |
| BR9713514A (pt) | Novo uso de creatina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM O ART. 8O DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C12N 15/87 (2006.01), A61K 47/62 (2017.0 |